Suppr超能文献

综述:非小细胞肺癌放射抵抗的机制和治疗视角。

Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancer.

机构信息

Provincial-Level Key Laboratory for Molecular Medicine of Major Diseases and The Prevention and Treatment with Traditional Chinese Medicine Research in Gansu Colleges and University, Gansu University of Chinese Medicine, Lanzhou, China.

Experimental & Training Teaching Centers, Gansu University of Chinese Medicine, Lanzhou, China.

出版信息

Front Immunol. 2023 Feb 14;14:1133899. doi: 10.3389/fimmu.2023.1133899. eCollection 2023.

Abstract

Radiotherapy is the major treatment of non-small cell lung cancer (NSCLC). The radioresistance and toxicity are the main obstacles that leading to therapeutic failure and poor prognosis. Oncogenic mutation, cancer stem cells (CSCs), tumor hypoxia, DNA damage repair, epithelial-mesenchymal transition (EMT), and tumor microenvironment (TME) may dominate the occurrence of radioresistance at different stages of radiotherapy. Chemotherapy drugs, targeted drugs, and immune checkpoint inhibitors are combined with radiotherapy to treat NSCLC to improve the efficacy. This article reviews the potential mechanism of radioresistance in NSCLC, and discusses the current drug research to overcome radioresistance and the advantages of Traditional Chinese medicine (TCM) in improving the efficacy and reducing the toxicity of radiotherapy.

摘要

放射治疗是非小细胞肺癌(NSCLC)的主要治疗方法。放射抵抗和毒性是导致治疗失败和预后不良的主要障碍。致癌突变、肿瘤干细胞(CSCs)、肿瘤缺氧、DNA 损伤修复、上皮-间充质转化(EMT)和肿瘤微环境(TME)可能在放射治疗的不同阶段主导放射抵抗的发生。化疗药物、靶向药物和免疫检查点抑制剂与放射治疗联合治疗 NSCLC,以提高疗效。本文综述了 NSCLC 放射抵抗的潜在机制,并讨论了目前克服放射抵抗的药物研究以及中药(TCM)在提高放疗疗效和降低毒性方面的优势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40ee/9971010/3d4d968c766e/fimmu-14-1133899-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验